PriceTargets.com logo

AVITA Medical - RCEL Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $27.80
  • Forecasted Upside: 196.38%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$9.38 As of 04/17/2024 01:00 AM ET
▼ -0.32 (-3.30%)

This chart shows the closing price for RCEL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AVITA Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RCEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RCEL

Analyst Price Target is $27.80
▲ +196.38% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for AVITA Medical in the last 3 months. The average price target is $27.80, with a high forecast of $40.00 and a low forecast of $21.00. The average price target represents a 196.38% upside from the last price of $9.38.

This chart shows the closing price for RCEL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 investment analysts is to moderate buy stock in AVITA Medical. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/11/2024BTIG ResearchDowngradeBuy ➝ NeutralLow
2/23/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$19.00 ➝ $21.00Low
2/23/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$22.00 ➝ $25.00Low
1/19/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$20.00 ➝ $22.00Low
11/21/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$20.00Low
11/10/2023Piper SandlerLower TargetOverweight ➝ Overweight$23.00 ➝ $19.00Low
10/19/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$26.00Low
9/26/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$26.00Low
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$26.00Low
8/11/2023Piper SandlerBoost TargetOverweight ➝ Overweight$18.50 ➝ $23.00Low
7/28/2023Bank of AmericaBoost TargetBuy$18.00 ➝ $27.00Low
7/13/2023Lake Street CapitalBoost TargetBuy$30.00 ➝ $40.00Low
6/27/2023Cantor FitzgeraldInitiated CoverageOverweight$23.00Low
6/20/2023BTIG ResearchBoost Target$19.00 ➝ $26.00Low
5/12/2023Piper SandlerBoost Target$16.00 ➝ $18.50Low
4/17/2023BTIG ResearchBoost TargetBuy$16.00 ➝ $19.00Low
3/1/2022BTIG ResearchLower Target$37.00 ➝ $21.00High
3/1/2022Piper SandlerLower Target$23.00 ➝ $15.00High
4/12/2021BTIG ResearchReiterated RatingBuy$41.00Medium
3/2/2021Piper SandlerInitiated CoverageOverweight$27.00High
8/30/2020OppenheimerReiterated RatingBuy$45.00Low
8/27/2020Bank of AmericaInitiated CoverageBuy$42.00High
7/9/2020BTIG ResearchBoost TargetBuy$8.00 ➝ $41.00High
7/6/2020OppenheimerBoost TargetOutperform$9.00 ➝ $45.00Low
6/18/2020BTIG ResearchReiterated RatingBuy$8.00Medium
6/15/2020OppenheimerInitiated CoverageBuy$9.00High
4/20/2020OppenheimerInitiated CoverageOutperform$9.00High
4/6/2020BTIG ResearchReiterated RatingBuy$8.00High
3/5/2020Lake Street CapitalReiterated RatingBuy$12.00High
3/3/2020BTIG ResearchInitiated CoverageBuy$10.00High
10/31/2019Lake Street CapitalBoost TargetBuy$10.00 ➝ $12.00Low
(Data available from 4/18/2019 forward)

News Sentiment Rating

0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2023
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2024
  • 7 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/19/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2024

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

AVITA Medical logo
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
Read More

Today's Range

Now: $9.38
Low: $9.34
High: $9.88

50 Day Range

MA: $15.95
Low: $9.38
High: $18.31

52 Week Range

Now: $9.38
Low: $9.16
High: $21.70

Volume

227,135 shs

Average Volume

203,680 shs

Market Capitalization

$241.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

Frequently Asked Questions

What sell-side analysts currently cover shares of AVITA Medical?

The following Wall Street analysts have issued research reports on AVITA Medical in the last year: Bank of America Co., BTIG Research, Cantor Fitzgerald, Lake Street Capital, and Piper Sandler.
View the latest analyst ratings for RCEL.

What is the current price target for AVITA Medical?

5 Wall Street analysts have set twelve-month price targets for AVITA Medical in the last year. Their average twelve-month price target is $27.80, suggesting a possible upside of 196.4%. Lake Street Capital has the highest price target set, predicting RCEL will reach $40.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $21.00 for AVITA Medical in the next year.
View the latest price targets for RCEL.

What is the current consensus analyst rating for AVITA Medical?

AVITA Medical currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RCEL.

What other companies compete with AVITA Medical?

Other companies that are similar to AVITA Medical include Utah Medical Products, Sight Sciences, AngioDynamics, Inovio Pharmaceuticals and Accuray. Learn More about companies similar to AVITA Medical.

How do I contact AVITA Medical's investor relations team?

AVITA Medical's physical mailing address is 28159 Avenue Stanford Suite 220, Valencia CA, 91355. The company's listed phone number is (833) 462-8482 and its investor relations email address is [email protected]. The official website for AVITA Medical is www.avitamedical.com. Learn More about contacing AVITA Medical investor relations.